Lincoln Pharmaceuticals Limited (BOM:531633)

Market Cap	12.97B -9.5%
Revenue (ttm)	6.60B +10.5%
Net Income	878.34M -1.7%
EPS	43.85 -1.7%
Shares Out	20.03M
PE Ratio	14.77
Forward PE	n/a
Dividend	1.80 (0.29%)
Ex-Dividend Date	Sep 12, 2025

Volume	93,775
Average Volume	5,840
Open	544.30
Previous Close	531.05
Day's Range	488.00 - 637.25
52-Week Range	439.95 - 688.90
Beta	0.12
RSI	82.51
Earnings Date	Feb 12, 2026

About Lincoln Pharmaceuticals

Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East As...

• Industry: Pharmaceutical Preparations
• Founded: 1979
• Employees: 1,853
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 531633

Financial Performance

In fiscal year 2025, Lincoln Pharmaceuticals's revenue was 6.23 billion, an increase of 7.35% compared to the previous year's 5.81 billion. Earnings were 823.46 million, a decrease of -11.74%.